Comparative field study evaluating the activity of recombinant Factor IX - Fc fusion protein (rFIXFc) in plasma samples at clinical haemostasis laboratories

被引：0
|
作者：
Sommer, J. [1 ]
Buyue, Y. [1 ]
Peters, R. T. [1 ]
Jiang, H. [1 ]
Gray, E. [2 ]
Pierce, G. F. [1 ]
机构：
[1] Biogen Idec Hemophilia, Waltham, MA USA
[2] NIBSC, Potters Bar, Herts, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：828 / 829
页数：2
相关论文
共 50 条
  • [41] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein ( rFIXFc) in the B-LONG and Kids B-LONG Studies
    Kulkarni, Roshni
    Shapiro, Amy D.
    Windyga, Jerzy
    Ragni, Margaret V.
    Pasi, K. John
    Ozelo, Margareth Castro
    Tsao, Elisa
    Mei, Baisong
    BLOOD, 2015, 126 (23)
  • [42] Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B
    Guillet, Benoit
    Yan, Songkai
    Hooper, Becky
    Drelich, Douglass
    Steenkamp, Jason
    Tomic, Radovan
    Mancuso, Maria Elisa
    ADVANCES IN THERAPY, 2024, 41 (02) : 649 - 658
  • [43] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX FC Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
    Windyga, J.
    Kulkarni, R.
    Shapiro, A. D.
    Ragni, M. V.
    Pasi, K. J.
    Ozelo, M. C.
    Tsao, E.
    Allen, G.
    Mei, B.
    HAEMOPHILIA, 2016, 22 : 19 - 20
  • [44] Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B
    Benoit Guillet
    Songkai Yan
    Becky Hooper
    Douglass Drelich
    Jason Steenkamp
    Radovan Tomic
    Maria Elisa Mancuso
    Advances in Therapy, 2024, 41 : 649 - 658
  • [45] Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
    Shapiro, Amy D.
    Chambost, Herve
    Ozelo, Margareth C.
    Falk, Aletta
    Ahlin, Helena
    Casiano, Sandra
    Santagostino, Elena
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
  • [46] Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals
    Dumont, Jennifer A.
    Loveday, Kenneth S.
    Light, David R.
    Pierce, Glenn F.
    Jiang, Haiyan
    THROMBOSIS RESEARCH, 2015, 136 (02) : 371 - 378
  • [47] Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol
    Clough, A. M.
    Gilreath, J. A.
    Mcpherson, J. . P.
    Link, N. C.
    Rodgers, G. M.
    Nance, D.
    HAEMOPHILIA, 2017, 23 (03) : E227 - E230
  • [48] In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products
    Turecek, Peter L.
    Ilk, Reinhard
    Gritsch, Herbert
    HAEMOPHILIA, 2024, 30 (01) : 151 - 160
  • [49] Clinical trial for long-lasting recombinant factor IX-FC (rFIXFc) in subjects with haemophilia B (B-LONG)
    Luk, A.
    Jiang, H.
    Gust, S.
    Defeo-Fraulini, T.
    Roberts, A.
    Pierce, G.
    HAEMOPHILIA, 2011, 17 (02) : 355 - 355
  • [50] Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, a recombinant factor IX Fc fusion protein
    Comerford, Claire
    Crowley, Maeve
    Collins, Norma
    Booth-Fleming, Brid
    Ryan-Hall, Annmarie
    Firtear, Brid
    O'Shea, Susan
    Duggan, Cleona
    HAEMOPHILIA, 2021, 27 (04) : E484 - E486
12345